ABOUT 18th_ELSF
​> AGENDA​
​> REGISTRATION​
​> PRESENTERS​
​> SPONSORS​
​> SUPPORTERS​
> NETWORKING​
> VENUE​
> ACCOMMODATION​

> ABOUT LAST YEAR​

20-minute presenters

Anocca AB

Anocca is leveraging its highly scalable precision analysis technologies to develop transformative TCR-T immunotherapies to treat cancer and other serious diseases. The company has pioneered a proprietary industrialised analytical cell biology platform that enables a deep understanding of disease specific T cell biology to deliver highly targeted cell-based therapies. The company’s innovative approach to deciphering T cell immunity can reach an unprecedented number of druggable targets in oncology and other therapeutic areas, such as infectious diseases and autoimmune disorders. Anocca has a fully integrated R&D infrastructure, with a range of scalable analytics platforms leveraging extensive libraries of engineered cells and complemented by a clinical manufacturing and process development facility. The company’s platform has generated a broad pipeline of blockbuster assets focusing on distinct disease franchises. The company expects to progress several TCR-T therapies to the clinic.

Anocca was founded in 2014 and is led by an experienced management team that has raised over USD 100 million in funding from leading Nordic investors Swedbank Robur Ny Teknik, Ramsbury Invest, Mellby Gård, Nidoco and Michano. Anocca’s team of over 65 employees operates from its site in Södertälje, Sweden.

www.anocca.com

Avata Biosciences

Avata Biosciences is conducting an expedited clinical development program in adult focal seizures with its lead asset AVAT-021, using the 505(b)(2) regulatory pathway. The objective is to launch Avata CBD capsules into the US epilepsy market (adult focal seizures) in 2029, driving revenues, which is the basis of the core Avata value proposition.
 
Avata Biosciences has recently achieved:                                                              
•    Positive comparative bioavailability results in a Phase 1 crossover study compared to Epidiolex®.
•    Pre-IND meeting feedback that enables pursuit of a 505(b)(2) pathway with Epidiolex® as the reference drug.
•    Completion of a selection process to determine the optimum US manufacturing site for a Tech Transfer.
 
In addition to the epilepsy program, Avata has recently agreed a collaborative partnership with Oxford University to develop AVAT-021 for patients with schizophrenia.
Avata recently launched a $110m funding round to support clinical and corporate development beyond Phase 3 studies. Avata is already in discussions with US venture capital groups and has received expressions of interest from neuropsychiatric strategic pharmaceutical companies interested in joining the round.

www.avatabio.com

Galimedix Therapeutics, Inc.

Galimedix is a Phase 2 clinical-stage private company developing novel oral and topical neuroprotective therapies with the potential to revolutionize the treatment of serious eye and brain diseases. Founded by a seasoned and highly dedicated team of bio-entrepreneurs, pharmaceutical executives and scientists, Galimedix’s groundbreaking small molecules offer the hope of changing the course of disease where amyloid beta (Aβ) plays a role, such as in dry age-related macular degeneration (AMD), glaucoma and Alzheimer’s disease – Galimedix’s initial areas of focus. The Company’s approach targets toxic Aβ oligomers and protofibrils.  Many studies have indicated that these oligomers and protofibrils are an underlying cause of neurodegenerative diseases of the eye. And, recent approvals and promising Phase 3 results of anti-Aβ drugs also have validated them as a key target in Alzheimer’s disease. Compelling pre-clinical data support the potential of Galimedix’s product candidates to slow or stop neurodegeneration and also restore lost neuronal function. A Phase 2 proof-of-concept study in dry AMD with lead program, topical GAL-101, is in preparation with strong support from partner, Théa Open Innovation (TOI). Clinical studies in other indications are planned for GAL-101 and for GAL-201, Galimedix oral drug for Alzheimer´s disease.

www.galimedix.com

iOmx Therapeutics AG

iOmx is a clinical-stage company that harnesses deep tumor and myeloid biology insights, along with its proprietary iOTarg™ target screening platform, to generate novel treatments for the most prevalent solid tumor indications. The company is translating unexplored immune evasion biology into a growing pipeline of biomarker-enabled drug programs. Focused on developing drugs with single agent activity, iOmx is creating potential new backbone therapies in a modality-open fashion. By applying its comprehensive drug discovery & development expertise iOmx is committed to shaping the future of cancer therapy.

iOmx is backed by international venture capital investors, such as ATHOS, Sofinnova Partners, Wellington Partners, MIG Capital as well as M Ventures. A EUR 65m Series B round was closed in September 2021.

www.iomx.com

Minoryx Therapeutics

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million.

www.minoryx.com

SpyBiotech

SpyBiotech is a clinical stage biotechnology company with novel vaccine platform technologies to target infectious diseases, cancer and chronic diseases.

www.spybiotech.com

TC Biopharm

We are committed to bringing improved medicines to patients as quickly as possible by creating efficient product development and clinical translation processes. We retain in-house control of the critical elements of drug development. At our operational headquarters in the UK, a diverse team of interdisciplinary scientists are optimizing new product candidates in our new state-of-the-art research complex. Experienced, dedicated personnel are creating quality-controlled products in our GMP cell and gene manufacturing suites. Our clinical group are working directly with physicians and hospitals around the world.

www.tcbiopharm.com

XYone Therapeutics Inc

XYone Therapeutics is a biotech startup seeking to develop drugs & diagnostic solutions for significant unmet medical needs in the fields of endocrine dysregulation & immuno-oncology.

www.xyonetx.com

10-minute presenters

AATec Medical GmbH

AATec Medical GmbH develops novel biotherapeutics for respiratory inflammatory diseases such as COPD, asthma, bronchiectasis and pulmonary infections. Our products are based on recombinant alpha-1 antitrypsin for inhalation. Driven by our passion to innovate we strive to provide urgently needed therapeutics to patients with severe respiratory diseases of highest medical need.

www.aatec-medical.com

ActiTrexx GmbH

We are a clinical Phase I/II biotech company focused on the development of cellular and biologic therapies for overshooting T cell mediated autoimmune and autoinflammatory diseases with high medical unmet needs.

With our lead cellular product, Actileucel (activated regulatory T cells), our goal is to prevent GvHD at an early stage and to provide a curative therapy with few side effects for patients undergoing blood stem cell transplantation for the first time. Actileucel is a safe and efficient treatment option that addresses a significant unmet medical need. Actileucel has the potential to overcome current risks and limitations inherent in stem cell transplantation.

www.actitrexx.de

AM-Pharma

AM-Pharma, a private biotech company based in Utrecht, the Netherlands, is developing its proprietary recombinant human alkaline phosphatase therapeutic, ilofotase alfa, for treatment of acute kidney injury and the rare disease hypophosphatasia.

www.am-pharma.com

biotx.ai GmbH

biotx.ai's causal AI mimics clinical trials in human genetic data.

Internally this has led to 3 drugs, each with high probability of success, now in clinical development.

www.biotx.ai

CIS BIOPHARMA AG

CIS BIOPHARMA helps cancer patients live longer and better lives. We are a biotechnology company dedicated to revolutionizing cancer treatment through novel targeted therapies. We are located in the area of Basel, Switzerland, a global hub for life sciences innovation. In our state-of-the-art laboratories, we pioneer groundbreaking technology to change the standard-of-care in oncology.

www.cisbiopharma.com

Innovent Biologics

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to discover and develop, manufacture and commercialize high-quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to discovering and developing, manufacturing and commercializing high-quality innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, and ophthalmology diseases to enhance the quality of the patients' lives. Innovent has 10 products in the market, 2 NDA under NMPA review, 5 assets in Phase III or pivotal clinical trials, and 19 more molecules in early clinical stage. Innovent has also entered into 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners. We strive to work with many collaborators to help advance the biopharmaceutical industry, improve drug availability and enhance the quality of the patients' lives.

www.innoventbio.com

Telum Therapeutics SL

Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Engineered Phage Lytic Proteins as new antimicrobial products.

www.telumtherapeutics.com

Rising Stars - Biotech Seed Companies Session

OncoBone Therapeutics Ltd

OncoBone representatives have a long history of working in CRO business and a large global network of high-quality CRO partners. OncoBone now offers this expertise to our clients as a Virtual CRO©.

www.oncobone.com

Procavea Biotech AG

At Procavea we're developing nonviral protein cages as carriers for the delivery of RNA Therapeutics to specific tissues in the body.

www.procavea.com

Sireau Labs Ltd

Sireau Labs is engineering solutions for rare diseases with science that is at the forefront of precision medicine. We are in a daily race to save lives stolen or impacted by rare disease.

www.sireau.com